In the present study we analyzed meningiomas and cultured meningioma cells to determine expression of inactive and active (phosphorylated) MAPK and used PD098059, a recently developed selective inhibitor of MAPK activity, 1, 7 to assess the role of MAPK in transduction of mitogenic signals from PDGF-BB in meningioma cells.
Materials and Methods

A Selective Inhibitor of MAPK Phosphorylation/Activation-PD098059
The PD098059 (2-[2Ј-amino-3Ј-methoxyphenyl]-oxananaphthalen-4-one) selectively inhibits the MAPK-activating enzyme MEK. Inhibition of MEK inhibits phosphorylation and activation of MAPK and consequent phosphorylation of MAPK substrates in cells in vitro. 7 A selective inhibitor, PD098059 does not affect the activity of a broad range of other protein kinases. 1 Results of doseresponse analysis of meningiomas has demonstrated the dose-dependent inhibition of MAPK at 25, 50, and 100 M, with the maximal inhibition of MAPK at 100 M PD098059 (data not shown).
Meningiomas and Meningioma Cell Cultures
Ten meningiomas were obtained in patients at the Vanderbilt University Hospital following procedures approved by the facility's Institutional Review Board. Representative central portions of these meningiomas were snap frozen and stored at Ϫ80˚C. Meningioma cells were cultured from central portions of an additional 10 meningiomas, as described previously, 8 after a frozen-section diagnosis had been made on adjacent tissue. Leptomeningeal cells were cultured from leptomeninges that had been peeled from two specimens of temporal lobes removed from patients with intractable seizures; these cells were cultured in a manner previously described. 9 For ultrastructural analysis, cells were grown in 35-mm dishes, fixed in 2% glutaraldehyde for 1 hour, gently scraped, and pelleted by centrifugation. The pellets were postfixed in 1% OsO 4 for 1 hour, after which they were embedded in epon. Thin sections were stained with uranyl acetate and lead citrate for ultrastructural analysis, which was performed with the aid of an electron microscope.
To assess the cultures, immunocytochemical analysis was performed on an initial meningioma cell culture, as previously reported. 8 Cells were plated onto two-well microscope slides for 1 day in supplemented DMEM and fixed in formalin. Immunocytochemical analysis was performed using the avidin-biotin-horseradish peroxidase method with mouse monoclonal antibodies against EMA, factor VIII, and GFAP.
For experiments outlined later in this report, only early passages (Passages 2-5) were used. Characteristics of the patients and their tumors are listed in Table 1 .
Expression of MAPK and Phosphorylated MAPK in Meningiomas
Lysates from tumors were prepared following standard procedures. While frozen, meningioma tumor tissue was diced, transferred to 3-ml cold hypotonic buffer-containing protease inhibitors (PMSF and aprotinin) on ice, and homogenized. After adding 10 l PMSF (10 mg/ml) for 30 minutes, the samples were transferred to microfuge tubes and spun at 14,000 rpm for 20 minutes at 4˚C. The supernatant was then respun, collected, and stored at Ϫ70˚C.
Expression of MAPK and Phosphorylated MAPK in Cultured Leptomeningeal and Meningioma Cells
Lysates from two primary leptomeningeal and six meningioma cell cultures were prepared, and Western blot analyses were performed with slight modifications of procedures described previously. 5 After treatments, the cells were washed with PBS and coated with lysis buffer containing 12.5 mM Tris HCl (pH 7.4), 2.5 mM EGTA, 1 mM ethylenediamine tetraacetic acid, 100 mM sodium fluoride, 5 mM dithiothreitol, 1% Triton X, 1 mM phenylmethylsulfonyl fluoride, 20 g/ml pepstatin, and 20 g/ml leupeptin. After a 10-minute incubation on ice at 4˚C, the plates were scraped and the lysates cleared by centrifugation as described earlier.
Effects of PD098059 on [ 3 H]Thymidine Incorporation and Cell Growth in Cultured Leptomeningeal and Meningioma Cells
Cells were plated at a concentration of 4 ϫ 10 4 cells/ml in 24-well dishes and grown to near confluence in DMEM containing 10% FBS; afterwards the cells were deprived of serum overnight. The following day the cells were again fed and treated with PD098059 (50 M or 100 M) or an equal volume (5 l/ml) of the vehicle DMSO. On Days 1 and 3 after treatment, the cells were pulsed with [ 3 H]thymidine (4 Ci/ml/well) for 6 or 12 hours. All conditions were created in triplicate. The plates were then washed three times with 10% trichloroacetic acid and the cells were solubilized with 0.2 N NaOH for scintillation counting. To determine cell-growth curves, cells from cultures MC5, MC7, and MC8 were plated in sixwell plates at 5 ϫ 10 4 cells per well, serum deprived overnight, and refed and treated with PD098059 or DMSO for 1 or 3 days. Cell counts of triplicate wells of cultures MC5, MC7, and MC8 were made using a cell counter.
Effects of PD098059 on MAPK Activation in Cultured Leptomeningeal and Meningioma Cells
The effects of PD098059 on MAPK activation were assesssed using Western blot analysis with a phosphospecific antibody to phosphorylated MAPK and by assaying the ability of MAPK to phosphorylate MBP (in the MBP kinase assay). Cells from cultures LC2 and MC5 through MC10 were cultured in growth medium containing 10% FBS to near confluence in 60-mm dishes, after which they were serum deprived overnight. The following day the cells were treated with either PD098059 (100 M) or an equal volume (5 l/ml) of DMSO in growth medium. Lysates were prepared on Days 1 and 3 after treatment, as described previously. 5 Protein concentrations were determined using the Bradford assay with bovine serum albumin as the standard. Equal amounts of protein were separated on sodium dodecyl sulfate-10% polyacrylamide gels and transferred to nitrocellulose by using a semidry transfer apparatus.
For MAPK Western blot analysis, membranes were blocked in Tris-buffered saline (pH 7.6) and 0.1% Tween 20 with 5% nonfat dry milk for 1 hour at room temperature; later the membranes were incubated with rabbit polyclonal anti-ERK1 overnight at 40˚C. This antibody reacts with MAPK(p44) (ERK1) and weakly with MAPK(p42) (ERK2). After washing, membranes were incubated with the horseradish peroxidase-conjugated secondary antibody for 1 hour at room temperature.
For Western blot analysis of phosphorylated MAPK, rabbit polyclonal antidiphosphorylated MAPK was used with horseradish peroxidase-conjugated donkey anti-rabbit as the secondary antibody following a modified manufacturer's protocol. The proteins were visualized with the aid of autoradiography by using enhanced chemiluminescence. To verify equal loading of protein on the gels, total protein stains were used.
Myelin Basic Protein Kinase Assay. Lysates were obtained from cultures MC5, MC6, and MC8 as described earlier. For each sample, lysis buffer was added to the protein (10-20 g) to a volume of 100 l. Immunoprecipitation was performed by adding 5 l each of anti-ERK1/MAPK(p44) and anti-ERK2/MAPK(p42) and rocking the samples at 4˚C for 1 to 2 hours. Each sample was given 20 l of protein A/G plus agarose and incubated for 1 hour. The samples were pelleted at 5000 rpm for 2 minutes at 4˚C, washed three times with lysis buffer, and once with kinase buffer (50 mM Tris [pH 7.4], 10 mM MgCl 2 , 2 mM EGTA, 0.1 mM NaVO 4 , 0.1 M aprotinin, 0.1 M leupeptin, 0.1 M PMSF). To perform the kinase assay, 30 l of reaction mix containing kinase buffer, 10 g/ml MBP, 10 M adenosine triphosphate, and a 10-Ci sample of 32-phosphorus was added to each pellet. The samples were then incubated at 30˚C for 15 minutes. To measure MAPK activity, phosphorylated MBP was resolved on sodium dodecyl sulfate-12% polyacrylamide gels, autoradiographs were obtained, and the bands were excised and counted.
Effects of PD098059 on PDGF-BB Stimulation of Meningioma Cell Proliferation
In a subsequent study we evaluated whether PD098059 blocked the mitogenic signal of PDGF-BB. For analysis of [ 3 H]thymidine incorporation, one primary leptomeningeal cell culture (LC2) and five primary meningioma cell cultures were deprived of serum for 24 hours and then treated with PDGF-BB (10 ng/ml) with or without 100 M PD098059 in media containing 0.4% FBS. The [ 3 H]thymidine incorporation was measured at 24 hours and 72 hours. All conditions were established in triplicate. In parallel, cell counts of representative primary cultures MC5 and MC9 were made. To assess the effects of PD098059 on MAPK activation after PDGF-BB treatment, Western blot analyses were performed on representative cultures with large numbers of early passage cells available by using a phosphospecific antibody to phosphorylated MAPK. Cells from cultures MC5, MC8, and MC9 were cultured in DMEM containing 10% FBS to near confluence in 60-mm dishes, serum deprived overnight, and treated in the manner described earlier. Lysates were prepared on Days 1 and 3 after treatment, as described earlier. Changes in [ 3 H]thymidine incorporation were evaluated using one-way analysis of variance.
Sources of Supplies and Equipment
The PD098059 was a kind gift from Dr. 
Results
Meningioma Cell Cultures
Meningioma cell cultures were populated by large polygonal cells with irregular, often interdigitating borders and centrally located oval nucleoli. A whorl formation was frequently seen. Ultrastructurally, all 10 primary meningioma cell cultures displayed features of meningiomas, including interdigitating cell membranes and desmosomes. Immunohistochemically, an initial meningioma cell culture exhibited EMA, but no GFAP or factor VIII immunostaining. The leptomeningeal cell cultures were initially populated by bipolar or polygonal cells with ovoid nuclei and prominent nucleoli, which became more uniformly polygonal with subsequent passages. Ultrastructurally, leptomeningeal cell cultures also exhibited desmosomes. Surface vesicles and endothelial granules were not present.
Expression of MAPK and Phosphorylated MAPK in Meningioma
Immunoblots demonstrated the presence of ERK1/ MAPK(p44) and ERK2/MAPK(p42) in lysates of 10 meningiomas ( Fig. 1 and data Signaling of MAPK and PDGF in meningiomas 
Expression of MAPK and Phosphorylated MAPK in Cultured Leptomeningeal and Meningioma Cells
Immunoblots demonstrated the presence of ERK1/ MAPK(p44) and ERK2/MAPK(p42) in lysates of both normal leptomeningeal cell cultures and in cultured cells from all four meningiomas tested (Fig. 2) . The antibody to phosphorylated MAPK demonstrated weak immunoreactivity in leptomeningeal cell lysates and intense immunostaining in lysates from each meningioma primary cell culture. Compared with leptomeningeal cells, MAPK appeared to be hyperphosphorylated in meningioma cells (Fig. 2) .
Effects of PD098059 on [ 3 H]Thymidine Incorporation and Cell Growth in Cultured Leptomeningeal and Meningioma Cells
The PD098059 produced a dose-and time-dependent inhibition of [ (Table 2 ). At a concentration of 100 M, PD098059 produced 52 to 84% inhibition of [ 3 H]thymidine incorporation in meningioma cell cultures on Day 3, compared with controls. In culture MC5, a 3-day PD098059 treatment was associated with a 22.2% reduction in cell counts compared with controls. In culture MC7, PD098059 was associated with a 14% and 20.9% reduction after 1 and 3 days, respectively, and in culture MC8 with a 13% and 15% reduction in cell counts, respectively.
Effects of PD098059 on MAPK Activity in Cultured Leptomeningeal Meningioma Cells
Treatment with PD098059 resulted in no apparent change in the levels of MAPK, but a nearly complete loss of phosphorylated MAPK immunoreactivity in LC2 cells after 1 and 3 days (data not shown). In all meningioma cell cultures, PD098059 treatment had no apparent effect on MAPK expression. A slight reduction in MAPK immunoreactivity on Day 3 in MC6 and MC10 cells reflects slight differences in loading. The PD098059 resulted in a graded reduction in phosphorylated MAPK immunoreactivity on Days 1 and 3 in each of the meningioma cell cultures, although in culture MC8, phosphorylated MAPK immunoreactivity was substantially reduced on Day 1 as well as on Day 3 (Fig. 3) .
Treatment with PD098059 for 1, 3, and 5 days produced 0%, 11.4%, and 48% inhibition of MBP kinase activity in MC5 cells; 6.2%, 44.3%, and 35.5% inhibition in MC6 cells; and 3.7%, 20%, and 13.7% inhibition of MBP kinase activity in MC8 cells, respectively.
Effects of PD098059 on PDGF-BB Stimulation of Meningioma Cell Proliferation
As illustrated in Fig. 4 , PDGF-BB produced a 1.3-to 1.5-fold increase in [ whereas on Day 3 PD098059 alone reduced proliferation to 92% of that in controls.
The PDGF-BB induced phosphorylation of MAPK on Days 1 and 3 in all three meningioma cell cultures studied (MC5, MC8, and MC9). Cotreatment with PD098059 again resulted in no apparent change in levels of MAPK, but reduced phosphorylated MAPK immunoreactivity after 1 and 3 days, with a greater reduction observed on Day 3, in all three meningioma cultures. Alone PD098059 had no effect on phosphorylated MAPK in MC5 cells, but reduced phosphorylated MAPK on Days 1 and 3 in MC8 cells and on Day 3 in MC9 cells (Fig. 5) .
Discussion
The findings we present indicate that MAPK is constitutively expressed in meningioma cells and, when activated by FBS or PDGF-BB, transduces mitogenic signals to these cells. Both MAPK and phosphorylated MAPK were identified in all 10 human meningiomas and in the cultured leptomeningeal and meningioma cells. Treatment with an inhibitor of MAPK kinase (MEK-1) activity reduced basal [ 3 H]thymidine incorporation and produced a dose-dependent inhibition of FBS-stimulated meningioma cell growth, which was associated with attenuation of MAPK phosphorylation and MAPK activity. Inhibition of MAPK activity also blocked PDGF-BB stimulation of meningioma cell proliferation. Thus, in leptomeningeal and meningioma cells, MAPK appears to be an important transducer of mitogenic signals such as those from PDGF-BB.
Constitutive expression and activation of MAPK was found in both meningiomas and meningioma cells, indicating MAPK expression and phosphorylation in meningiomas. The finding of less pronounced phosphorylation in several meningiomas most likely reflects dephosphorylation during the variable intervals between removal of the tumor, completion of intraoperative diagnostic efforts, and subsequent freezing of tumor tissue (in contrast to the rapid freezing of cell lysates). Constitutive expression and activation of MAPK has also been found in breast epithelium, benign fibroadenomas, and fibrocystic disease, all of which exhibited comparable MAPK activity. 21 In breast carcinoma, phosphorylated MAPK activity was increased
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Signaling of MAPK and PDGF in meningiomas five to 10 times that observed in benign processes. Moreover, there was significant overexpression of MAPK messenger RNA suggesting that overexpression may be an important element in malignant transformation of breast epithelium. 11 Similarly, constitutive MAPK expression has been found in normal brain, low-and high-grade astrocytomas, and oligodendrogliomas. In gliomas, greater MAPK levels have been observed in high-grade astrocytomas and, particularly, in anaplastic oligodendrogliomas. 13 Thus, accumulating evidence indicates that MAPKs transduce mitogenic signals in a number of neoplastic processes.
Our studies demonstrate that PD098059 inhibits growth of meningioma cells by inhibiting activation of MAPK. Treatment with PD098059 produced progressive growth inhibition, correlating with a marked reduction in MAPK phosphorylation and reduced MAPK activity, without changing levels of unphosphorylated MAPK(p44) and MAPK(p42) in most of the cell cultures. This indicates that the major mechanism by which PD098059 inhibits MAPK is by inhibition of phosphorylation/activation, rather than by reduction of MAPK synthesis. Inhibition at other sites is also unlikely because previous studies have shown that PD098059 does not inhibit numerous kinases, including EGF receptor kinase, insulin receptor kinase, PDGF receptor kinase, Raf kinase, cyclic adenosine monophosphate-dependent kinase, protein kinase C, JNK, MAPKAP kinase-1, and MEK. 1, 7 Reversal of meningioma cell growth inhibition after withdrawal of PD098059 indicates that its effects are reversible and not due to nonspecific cytotoxic effects. Due to limitations in solubility, the maximum dose of PD098059 used in this study was 100 M, which produced partial inhibition of MAPK activity, [ 3 H]thymidine incorporation, and MAPK phosphorylation. These findings are similar to previous reports that PD098059 partially inhibited MEK after treatment with serum or tissue plasminogen activator, but showed less inhibition after treatment with potent cell mitogens such as high-dose EGF. 1, 7 Treatment of stimulated cells with PD098059 resulted in a 60 to 84% reduction in [ In meningiomas, the intermediary links between the PDGF-␤ receptor tyrosine kinase and MAPK have not been identified. However, in many cells, the PDGF-␤ receptor activates the low-molecular-weight guanosine triphosphatase Ras protein, which functions as a signaling mediator 16 and activates MAPK kinase (MEK-1). Although ras mutations have not been reported in meningiomas, expression of dominant negative H-ras mutations in meningioma cells inhibits their growth, 20 14 Moreover, transformation by ras may be blocked by PD098059. Thus, limited evidence indicates that the PDGF-␤ receptor tyrosine kinase in meningiomas activates MAPK, at least in part through the Ras-Raf MAPK pathway. Although results of several studies demonstrate that PDGF-␤-receptor activation of a Ras-Raf MAPK pathway is central to transduction of the PDGF receptor's mitogenic signals, other pathways may be involved. Ligand binding to the PDGF-␤ receptor phosphorylates PI3K, another G protein-associated kinase that participates in growth signaling that may directly activate MAPK, at least in smooth-muscle cells. 6 However, our preliminary findings indicate that any PDGF-␤ receptor R activation of PI3K influences cell proliferation by mechanisms independent of MAPK, possibly involving a PI3K-p70 s6 pathway (Johnson, et al., unpublished observations). Activation of PI3K has been shown to stimulate cell division through a PI3K-protein kinase B-p70 s6 pathway in smooth-muscle cells. 23 Thus, although transduction of mitogenic signals from the PDGF-␤ receptor requires the PDGF-␤ receptor-MAPK pathway, other downstream signal effectors may be involved. 5 Future studies may clarify which PDGF-␤ receptor-activated pathways interact with MAPK to stimulate meningioma cell growth.
Conclusions
These studies have shown that MAPK is present and activated in meningiomas. Moreover, MAPK transduces mitogenic signals of PDGF-␤ receptor tyrosine kinase and, probably, other growth factor receptor tyrosine kinases on meningioma cells. These findings raise the possibility that recently developed inhibitors of MAPK activity might be useful as adjunctive treatments for inoperable, recurrent, or malignant meningiomas in humans.
